Development of RNAi as Treatment for Neurodegeneration

RNAi 治疗神经退行性疾病的发展

基本信息

批准号：
8084139
负责人：
KENNETH Stephen KOSIK
金额：
$ 12.68万
依托单位：
UNIVERSITY OF CALIFORNIA SANTA BARBARA
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-09-15 至 2013-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8084139
关键词：
3xTg-AD mouse Age Alzheimer&apos s Disease Animal Model Animals Award Brain Diseases Caring Cell Culture Techniques Collaborations Communication Core Facility Data Detection Development Disease Enzymes Evaluation Exploratory/Developmental Grant for Diagnostic Cancer Imaging Functional disorder Funding Genotype Goals Grant Inherited Injection of therapeutic agent Institutes Investigation Laboratories Lesion Link Long-Term Potentiation Measurement Messenger RNA Methods Microscopy Mus Needs Assessment Nerve Degeneration Neurofibrillary Tangles Neurons Outcome Measure Population Positioning Attribute Procedures Process Proteins RNA Interference Research Research Infrastructure Retirement Site Small Interfering RNA Subfamily lentivirinae Synapses Technology Therapeutic Transgenes Transgenic Mice Transgenic Model Universities Validation Vertebral column Viral Viral Vector beta-site APP cleaving enzyme 1 design efficacy testing gene therapy knock-down neuropathology prevent programs protein aggregate small hairpin RNA tau Proteins tau-1 therapeutic target

项目摘要

DESCRIPTION (provided by applicant): Alzheimer's disease, already a serious global disease afflicting large segments of the population, is about to burgeon into an even larger problem as the baby-boomer bubble approaches retirement age. The disease remains incurable; however validated therapeutic targets are known. RNA interference (RNAi) technology poses a potential therapeutic option which requires further investigation. Targeting the mRNA rather than the protein offers major advantages in the ease of designing a highly specific inhibitory agent and rapidly advancing approaches to RNAi delivery suggest that the method can be developed into a therapy. Our hypothesis is that RNAi will prove to be an effective and selective strategy to slow, and perhaps even reverse, the pathogenic processes in inherited and sporadic AD. This proposal follows the completion of an R21 award of the same title. The announcement for this award was an RFA from the Fogarty Institute for proposals related to Brain Disorders in the Developing World and a major goal of the program was to build research capacity at the foreign site. The successful completion of the R21 aims is described in the preliminary data. The collaborative effort poses two questions concerning the cause and possible treatment of neurofibrillary pathology in AD. One question is whether suppression of Cdk5, an increasingly accepted disease target, can modify neurofibrillary pathology in an animal model. Cdk5 is an enzyme that phosphorylates tau protein and in so doing is thought to contribute to the conversion of the protein into an insoluble aggregate known as the neurofibrillary tangle. Cdk5 will be targeted by RNAi delivered in a viral vector. The second question is whether BACE1 inhibition by RNAi delivery can retard or prevent the development of neurofibrillary pathology in an animal with both plaques and tangles. The studies proposed here are intended to continue building research capacity at the foreign site which is now in a position to launch these studies. In addition to the established collaboration between the Kosik laboratory and the foreign site, two consultants will contribute to capacity building. They are Bev Davidson who will advise on the establishment of a viral core and Frank LaFerla who will contribute the triple transgenic mice to the vivarium at the foreign site.

描述（由申请人提供）：阿尔茨海默氏病已经是一种严重的全球疾病，遭受了大部分人口的困扰，随着婴儿潮一代的泡沫接近退休年龄，将会陷入更大的问题。该疾病仍然无法治愈；但是，已知有验证的治疗靶标。 RNA干扰（RNAI）技术提出了一种潜在的治疗选择，需要进一步研究。靶向mRNA而不是蛋白质在设计高度特异性抑制剂和快速前进的RNAi递送方法方面具有主要优势，这表明该方法可以发展为治疗。我们的假设是，RNAi将被证明是一种有效且有选择性的策略，可以减慢遗传和零星AD中的致病过程。该建议是在获得同一标题的R21奖项之后的。该奖项的宣布是与发展中国家脑疾病有关的Fogarty提案研究所的RFA，该计划的主要目标是在外国现场建立研究能力。 R21 AIM的成功完成在初步数据中描述了。协作努力提出了两个有关AD中神经原纤维病理原因和可能治疗的问题。一个问题是，抑制CDK5是一种日益接受的疾病靶标，是否可以改变动物模型中的神经原纤维病理。 CDK5是一种磷酸化tau蛋白的酶，因此被认为有助于将蛋白质转化为一种被称为神经原纤维缠结的不溶性骨料。 CDK5将由病毒载体中传递的RNAi靶向。第二个问题是RNAi递送抑制的BACE1是否可以阻碍或阻止具有斑块和缠结的动物中神经原纤维病理的发展。这里提出的研究旨在继续在外国站点建立研究能力，该研究能力现在可以启动这些研究。除了Kosik实验室与外国现场的既定合作外，两名顾问还将为能力建设做出贡献。他们是贝夫·戴维森（Bev Davidson），他将为建立病毒核心和弗兰克·拉弗拉（Frank Laferla）提供建议，他们将向外国现场的Vivarium贡献三重转基因小鼠。

项目成果

期刊论文数量（11）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

p120-catenin is necessary for neuroprotection induced by CDK5 silencing in models of Alzheimer's disease.

DOI：
10.1111/jnc.13697
发表时间：
2016-08
期刊：
Journal of neurochemistry
影响因子：
4.7
作者：
Uribe-Arias A;Posada-Duque RA;González-Billault C;Villegas A;Lopera F;Cardona-Gómez GP
通讯作者：
Cardona-Gómez GP

Linalool reverses neuropathological and behavioral impairments in old triple transgenic Alzheimer's mice.

DOI：
10.1016/j.neuropharm.2015.11.002
发表时间：
2016-03
期刊：
Neuropharmacology
影响因子：
4.7
作者：
Sabogal-Guáqueta AM;Osorio E;Cardona-Gómez GP
通讯作者：
Cardona-Gómez GP

Exploratory data from complete genomes of familial alzheimer disease age-at-onset outliers.

DOI：
10.1002/humu.22167
发表时间：
2012-12
期刊：
HUMAN MUTATION
影响因子：
3.9
作者：
Lalli, Matthew A.;Garcia, Gloria;Madrigal, Lucia;Arcos-Burgos, Mauricio;Arcila, Mary Luz;Kosik, Kenneth S.;Lopera, Francisco
通讯作者：
Lopera, Francisco

The flavonoid quercetin ameliorates Alzheimer's disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer's disease model mice.

DOI：
10.1016/j.neuropharm.2015.01.027
发表时间：
2015-06
期刊：
Neuropharmacology
影响因子：
4.7
作者：
Sabogal-Guáqueta AM;Muñoz-Manco JI;Ramírez-Pineda JR;Lamprea-Rodriguez M;Osorio E;Cardona-Gómez GP
通讯作者：
Cardona-Gómez GP

Long- and short-term CDK5 knockdown prevents spatial memory dysfunction and tau pathology of triple transgenic Alzheimer's mice.

长期和短期 CDK5 敲低可预防三重转基因阿尔茨海默病小鼠的空间记忆功能障碍和 tau 病理学。